Isp7 is a novel regulator of amino acid uptake in the TOR signaling pathway

Dana Laor, Adiel Cohen, Metsada Pasmanik-Chor, Varda Oron-Karni, Martin Kupiec, Ronit Weisman

Research output: Contribution to journalArticlepeer-review


Tor proteins reside in two distinct complexes, TOR complexes 1 and 2 (TORC1 and TORC2), that are central for the regulation of cellular growth, proliferation, and survival. TOR is also the target for the immunosuppressive and anticancer drug rapamycin. In Schizosaccharomyces pombe, disruption of the TSC complex, mutations in which can lead to the tuberous sclerosis syndrome in humans, results in a rapamycin-sensitive phenotype under poor nitrogen conditions. We show here that the sensitivity to rapamycin is mediated via inhibition of TORC1 and suppressed by overexpression of isp7+, a member of the family of 2-oxoglutarate- Fe(II)-dependent oxygenase genes. The transcript level of isp7+ is negatively regulated by TORC1 but positively regulated by TORC2. Yet we find extensive similarity between the transcriptome of cells disrupted for isp7+ and cells mutated in the catalytic subunit of TORC1. Moreover, Isp7 regulates amino acid permease expression in a fashion similar to that of TORC1 and opposite that of TORC2. Overexpression of isp7+ induces TORC1-dependent phosphorylation of ribosomal protein Rps6 while inhibiting TORC2-dependent phosphorylation and activation of the AGC-like kinase Gad8. Taken together, our findings suggest a central role for Isp7 in amino acid homeostasis and the presence of isp7+-dependent regulatory loops that affect both TORC1 and TORC2.

Original languageEnglish
Pages (from-to)794-806
Number of pages13
JournalMolecular and Cellular Biology
Issue number5
StatePublished - Mar 2014


Dive into the research topics of 'Isp7 is a novel regulator of amino acid uptake in the TOR signaling pathway'. Together they form a unique fingerprint.

Cite this